Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Research dashboard

Search approved medicines for AI-predicted activity against four drug-resistant pathogens, and see what evidence is already documented for each one.

TryTuberculosisMRSAKlebsiella infectionE. coli infection

1,761

Approved medicines

Approved medicines matched to the FDA Orange Book, antimicrobials included

1,276

Medicines with ≥40% AI-predicted activity

Against at least one of the four supported pathogens; each medicine counted once

1,019

Repurposing candidates

Of those, the medicines that are not already antimicrobials

How the repurposing candidates are counted

  1. 1,761approved medicines

  2. 1,276with AI-predicted activity ≥40% against at least one pathogen

    − 485 below ≥40%, not counted

  3. 1,120not already antimicrobials

    − 156 already antimicrobials, set aside

  4. 1,019repurposing candidates

    − 101 needing review, kept in the library

Existing antimicrobials are identified from WHO ATC codes and FDA pharmacologic classes. Medicines needing review (neither source says whether they are antimicrobials) stay in the approved-medicine download, marked “unclassified”. They are not assumed to be non-antimicrobials, so they are not counted as candidates.

Downloads

Download approved medicines (CSV)1,761 rowsDownload repurposing candidates (CSV)1,019 rows

Pathogen coverage

A medicine can count under more than one

Registered studies

A registration describes a study; it does not establish a positive result.

Condition
When these studies started38,873 of 39,548 have a start date · most in 2021 (1,903)
193119812030

  • A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause

    NCT07829653 · start 2026-10-31

    Registered record
    Registry ID
    NCT07829653
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-31
    Completion
    2028-04-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant
    PhasePhase 3
    Registry statusNot yet recruiting

  • Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)

    NCT07528690 · start 2026-10-30

    Registered record
    Registry ID
    NCT07528690
    Conditions
    Hepatic Encephalopathy; Cirrhosis
    Interventions
    Microbiota transplant therapy (MTT) capsules; Placebo capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-30
    Completion
    2031-03-03
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy; Cirrhosis
    InterventionMicrobiota transplant therapy (MTT) capsules; Placebo capsule
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

    NCT07595042 · start 2026-10-30

    Registered record
    Registry ID
    NCT07595042
    Conditions
    Tuberculosis
    Interventions
    Isoniazid; Rifampin; Pyrazinamide; Ethambutol; Rifapentine; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-30
    Completion
    2029-10-22
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazid; Rifampin; Pyrazinamide; Ethambutol +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

    NCT07748208 · start 2026-10-30

    Registered record
    Registry ID
    NCT07748208
    Conditions
    Breast Cancer; Diabetes Type II
    Interventions
    Inavolisib; Fulvestrant; Palbociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-30
    Completion
    2029-09-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Diabetes Type II
    InterventionInavolisib; Fulvestrant; Palbociclib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML

    NCT07828535 · start 2026-10-30

    Registered record
    Registry ID
    NCT07828535
    Conditions
    Acute Myeloid Leukemia (AML)
    Interventions
    Liposome Mitoxantrone; Venetoclax; Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10-30
    Completion
    2032-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia (AML)
    InterventionLiposome Mitoxantrone; Venetoclax; Azacitidine
    PhasePhase 1
    Registry statusNot yet recruiting

  • Efficacy and Safety of Inhaled Peramivir Solution for the Treatment of Adults With Uncomplicated Influenza

    NCT07791251 · start 2026-10-28

    Registered record
    Registry ID
    NCT07791251
    Conditions
    Influenza Infection
    Interventions
    Peramivir Inhalation Solution; Placebo for Peramivir Inhalation Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-28
    Completion
    2028-05-06
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfluenza Infection
    InterventionPeramivir Inhalation Solution; Placebo for Peramivir Inhalation Solution
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies

    NCT06628687 · start 2026-10-26

    Registered record
    Registry ID
    NCT06628687
    Conditions
    Friedreich Ataxia
    Interventions
    Omaveloxolone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-10-26
    Completion
    2035-04-30
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFriedreich Ataxia
    InterventionOmaveloxolone
    PhaseNot recorded
    Registry statusRecruiting

  • Intranasal Nafarelin For Triggering Oocyte Maturation

    NCT06763926 · start 2026-10-15

    Registered record
    Registry ID
    NCT06763926
    Conditions
    Fertility Preservation
    Interventions
    Subcutaneous Triptorelin; Intranasal nafarelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-10-15
    Completion
    2028-01-15
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFertility Preservation
    InterventionSubcutaneous Triptorelin; Intranasal nafarelin
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

    NCT07124559 · start 2026-10-15

    Registered record
    Registry ID
    NCT07124559
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; Isoniazid; Dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-15
    Completion
    2028-05-31
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; Isoniazid; Dolutegravir
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

    NCT07543172 · start 2026-10-15

    Registered record
    Registry ID
    NCT07543172
    Conditions
    Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
    Interventions
    Adagrasib; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-15
    Completion
    2029-06-01
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
    InterventionAdagrasib; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Cefepime/Enmetazobactam for Bacteremic Complicated Urinary Tract Infections

    NCT07725848 · start 2026-10-15

    Registered record
    Registry ID
    NCT07725848
    Conditions
    Complicated Urinary Tract Infections; Antibiotic Resistance
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-10-15
    Completion
    2029-10-15
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infections; Antibiotic Resistance
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

    NCT07598110 · start 2026-10-10

    Registered record
    Registry ID
    NCT07598110
    Conditions
    Acute Myeloid Leukemia
    Interventions
    fludarabine and treosulfan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-10
    Completion
    2031-02-10
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    Interventionfludarabine and treosulfan
    PhasePhase 2
    Registry statusNot yet recruiting

  • AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")

    NCT07649304 · start 2026-10-09

    Registered record
    Registry ID
    NCT07649304
    Conditions
    AIDS-Related Diffuse Large B-cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8; Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8; Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8; Plasmablastic Lymphoma; Primary Effusion Lymphoma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Cyclophosphamide; Doxorubicin Hydrochloride; Echocardiography Test; Glofitamab; Positron Emission Tomography; Prednisone; Questionnaire Administration; Rituximab; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10-09
    Completion
    2028-04-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAIDS-Related Diffuse Large B-cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified +5 more
    InterventionBiopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy +10 more
    PhasePhase 1
    Registry statusNot yet recruiting

  • Lemborexant on Perioperative Sleep Quality in Patients Undergoing Thoracoscopic Surgery

    NCT07811401 · start 2026-10-08

    Registered record
    Registry ID
    NCT07811401
    Conditions
    Postoperative Sleep Disturbance; Thoracoscopic Surgery
    Interventions
    Lemborexant 5 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-08
    Completion
    2028-06-01
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Sleep Disturbance; Thoracoscopic Surgery
    InterventionLemborexant 5 mg; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India

    NCT07806591 · start 2026-10-05

    Registered record
    Registry ID
    NCT07806591
    Conditions
    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Interventions
    Darolutamide plus androgen deprivation therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-10-05
    Completion
    2028-10-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    InterventionDarolutamide plus androgen deprivation therapy
    PhaseNot recorded
    Registry statusNot yet recruiting

AI-predicted activity is a model’s estimate that a molecule is active against a pathogen in the laboratory. It is not clinical effectiveness. The models describe each pathogen species; the data behind them rarely records resistant strains.